Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

O'Hare, Thomas, Walters, Denise K., Stoffregen, Eric P., Jia, Taiping, Manley, Paul W., Mestan, Jürgen, Cowan-Jacob, Sandra W., Lee, Francis Y., Heinrich, Michael C., Deininger, Michael W.N., Druker, Brian J. · 2005 · Cancer Research

Published version of a preprint

Abstract

Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired imatinib resistance has been traced to Bcr-Abl kinase domain mutations with decreased imatinib sensitivity. Thus, alternate Bcr-Abl kinase inhibitors that have activity against imatinib-resistant mutants would be useful for patients who relapse on imatinib therapy. Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. In the current article, we compared imatinib, AMN107, and BMS-354825 in cellular and biochemical assays against a panel of 16 kinase domain mutants representing >90% of clinical isolates. We report that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for all imatinib-resistant mutants tested, with the exception of T315I. Thus, both inhibitors hold promise for treating imatinib-refractory CML.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-05-0259

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 1,036

Metadata

Authors
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., & Druker, B. J.
Affiliations
  • 1Howard Hughes Medical Institute and
  • Howard Hughes Medical Institute (US)
  • Oregon Health & Science University (US)
  • Novartis (Switzerland) (CH)
  • 4Novartis Institutes for Biomedical Research, Basel, Switzerland; and
  • Bristol-Myers Squibb (United States) (US)
  • Portland VA Medical Center (US)
Venue
Cancer Research
Published
2005-06-01
Volume
65
Issue
11
Pages
4500-4505
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2097946794
Cited by
1,036
References
24
Citations by year
2026: 11 · 2025: 15 · 2024: 22 · 2023: 16 · 2022: 31 · 2021: 34 · 2020: 27 · 2019: 26 · 2018: 39 · 2017: 33 · 2016: 35 · 2015: 33 · 2014: 37 · 2013: 59 · 2012: 62
FWCI
52.97
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
BCR-ABL tyrosine kinase inhibitors, imatinib resistance, nilotinib, imatinib, chronic myeloid leukemia, BCR-ABL kinase domain mutations, T315I mutation, tyrosine kinase inhibitors, drug potency comparison
MeSH terms
Imatinib Mesylate, Dasatinib, Animals, Antineoplastic Agents, Benzamides, Cell Line, Models, Molecular, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Thiazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Protein Structure, Tertiary, Protein Kinase Inhibitors, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-0259
The paper
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., & Druker, B. J. (2005). In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-0259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.